Drug Interactions refer to modifications in a drug's effects brought on by recent or contemporaneous use of another drug or medicines (drug-drug interactions), ingesting food (drug-nutrient interactions), or ingesting dietary supplements (dietary supplement-drug interactions). A drug-drug interaction may make one or both medications work more or less effectively. Clinically relevant interactions are typically unintended and frequently predicted. Therapeutic failure or negative consequences might happen. Rarely can a practitioner employ known drug-drug interactions to achieve a desired treatment outcome. For instance, co-administration of lopinavir with ritonavir to HIV-infected individuals causes changes in lopinavir metabolism and enhances serum lopinavir concentrations and efficacy. When two medications with comparable qualities are taken together, the effects are cumulative. When two medications with comparable qualities are taken together, the effects are cumulative. For instance, using a benzodiazepine for anxiety and a different one before night for sleeplessness may have a cumulative impact and cause poisoning.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia